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The kidney, a cardiovascular risk marker, and a new target for
therapy. Both reduced filtration power and increased excretion
of albumin in the urine are powerful markers for renal and
cardiovascular progressive function loss. These risk markers
indicate the risk above and beyond the conventional existing
risk markers/factors. The risk is substantial, because both re-
duced filtration and microalbuminuria are highly prevalent in
the general population, matching in prevalence with the most
well-known risk factor, hypertension.
Therapeutic interventions to preserve renal and cardio-
vascular function, such as with angiotensin-converting enzyme
inhibitors and angiotensin II receptor antagonists, are highly ef-
fective, particularly in those patients that have reduced filtration
power. In addition, short-term reduction of albuminuria that
follows the renin-angiotensin-aldosterone-system intervention
appears to be predictive of long-term cardiovascular and renal
protection.
In conclusion, estimated glomerular filtration rate as well
as albumin excretion in the urine are powerful predictors for
cardiovascular and renal outcome and should be used as such.
Intervention and prevention could be aimed at not only at re-
ducing conventional risk markers, but also at reducing albumin-
uria.
Classic cardiovascular (CV) risk profiling is based on
age, gender, blood pressure, cholesterol, smoking, body
weight, and type 2 diabetes. The combination of most
of these factors renders the doctor the Framingham risk
score. This allows us to classify the CV risk of a patient in
the office. In addition, it also allows us to initiate and jus-
tify our therapeutic strategies. These therapies are aimed
at reducing modifiable risk factors and markers, thereby
hopefully reducing CV and renal risk. Indeed, there is an
intriguing overlap between the kidney and the heart in
this respect. Lowering blood pressure has a marked ef-
fect on preventing further end-organ damage, both with
respect to CV and renal end points. Recently, lowering of
cholesterol has been added to this CV and renal protec-
tive armamentarium. With respect to diabetes, metabolic
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control was a big step in preventing the life-threatening
end-organ effects of diabetes, which reduces renal as well
as CV risk. Reduction of smoking and body weight has
also been associated with CV protection, and protective
effects on the kidney are suggested.
Despite the armamentarium of risk profilers and re-
lated therapies, CV and renal protection remains subop-
timal, in that many patients progress to end-stage renal
disease or show CV morbidity or mortality despite opti-
mal treatment. Thus, the search for newer, better pre-
dictors or, more importantly, new therapy targets, has
been ongoing. Aside from parameters reflecting general
inflammation (among others, C-reactive protein), an in-
triguing relation was recently revealed between the kid-
ney and the CV system, which allows novel approaches to
CV risk profiling and therapy. Both the level of glomeru-
lar filtration rate, as well as the level of albumin leakage
in the urine appear to be extremely potent markers for
CV and renal disease progression.
The purpose of this short review is to define renal
dysfunction as the new risk marker for CV and renal
end-organ damage and, more importantly, to mark albu-
minuria as the novel target for therapy of the 21st century
to prevent CV and renal disease progression.
RENAL FILTRATION AS A CV RISK MARKER
Recently, several population surveys established that
renal function, measured as estimated glomerular filtra-
tion rate (eGFR), varies considerably between individ-
uals, and that unrecognized loss of filtration power and
chronic kidney disease (CKD) is relatively common. The
estimated prevalence of CKD, defined as an eGFR <60
mL/min, is 6.3% in the United States [1]; when defined
as a combination of eGFR <60 or eGFR >60 + microal-
buminuria/proteinuria, the estimated prevalence is even
higher, 11%. In our town, Groningen, we conducted a
survey among the general population and indeed found
that the normal value of eGFR is frequently reduced in
the normal population (Table 1). Classifying CKD as an
eGFR<60, we found close to 8% prevalence and, adding
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Table 1. Distribution of renal function (eGFR) in the “general”
population in Groningen, The Netherlands, in the PREVEND study
(left panel)
eGFR distribution CKD distribution
eGFR
mL/min N % CKD stage N %
8459 8459
>90 2043 24 (23) I (>90 + Alb) 225 2.7 (1.3)
60–90 5918 69 (71) II (60–90 + Alb) 771 9.1 (3.8)
30–60 487 5.7 (5.3) III (30–60) 487 5.7 (5.3)
15–30 8 0.1 (0.04) IV (15–30) 8 0.1 (0.04)
<15 3 0.04 (0) V (<15) 3 0.04 (0)
Abbreviations are: eGFR, estimated glomerular filtration rate; MDRD,
Modification of Diet in Renal Disease (study); PREVEND, Prevention of
Renal and Vascular End-stage Disease; CKD, chronic kidney disease; K/DOQI,
Kidney Disease Outcomes Quality Initiative; GFR, glomerular filtration rate;
Alb, albumin.
eGFR is estimated with the simplified MDRD formula. CKD is staged accord-
ing to the K/DOQI guidelines. CKD was defined as a GFR <60 or a GFR >60
+ albuminuria >30 mg/24 h (right panel). Because the total PREVEND study
population of 8459 patients was enriched for the presence of microalbuminuria,
distribution was also calculated in the true random sample from the general
population (N = 2489). Bold percentages in parentheses are given as those rep-
resenting the distribution of eGFR and CKD in this unselected population cohort.
the group with an eGFR >60 with microalbuminuria or
proteinuria, we found CKD to be present in 12% of the
general population (Table 1). Thus, both studies show that
CKD has a high prevalence.
Raised levels of serum creatinine or reduced levels of
eGFR are associated with increased CV risk, as is found
in many different studies and populations. Not only can
this be found in already at-risk populations such as in
those with heart failure [2] and postmyocardial infarc-
tion (Captopril and Thrombolysis Study trial) [3], it is
also present in hypertensive or at-risk populations [Heart
Outcomes Prevention Evaluation (HOPE)] [4], and even
in the general population [Prevention of Renal and Vas-
cular End-stage Disease (PREVEND)] [5]. In all these
studies, relatively mild reduction in eGFR (around 60–80
mL/min) was already associated with increased CV risk.
Combining the epidemiology of renal function levels in
the general population and the CV risk in at-risk popula-
tions, one can see that we are dealing with the kidney as
a potentially important risk marker of CV disease.
Although the exact mechanism of this relation is not
understood, one could hypothesize that decreased renal
function is associated with neurohormonal changes (pos-
sibly compensating for the reduction in glomerular filtra-
tion rate). These hormones, such as angiotensin, may, in
turn, cause aggravation of cardiac problems. If true, then
angiotensin would be an important target for protecting
the kidney and the heart in patients with reduced renal
function.
RISK REDUCTION BY TREATMENT OF
PATIENTS WITH REDUCED RENAL FUNCTION
There is, unfortunately, no evidence yet that increas-
ing renal function, by, for instance, growing new kidney
tissue, will reduce CV or renal risk, which would be an ex-
tremely interesting approach. We do have evidence that
intervening in the renin-angiotensin-aldosterone system
(RAAS) gives CV and renal protection, particularly in
those that have reduced renal function. Hillege et al [3]
showed that angiotensin-converting enzyme (ACE) in-
hibition rendered CV protection postmyocardial infarc-
tion, more so for those with lower starting eGFR (Fig. 1).
Similarly, Mann et al demonstrated that ACE inhibition
was at least as cardioprotective in those CV-risk patients
that had the lowest eGFR (HOPE) [4]. Also, in patients
with more advanced diabetic nephropathy, angiotensin II
receptor antagonists show at least as good or even better
renal and cardiac protection when eGFR is lower com-
pared with higher [6]. In other words, low glomerular
filtration rate may be an excellent CV risk marker, and it
also identifies a group of patients that is as good or even
better at responding to cardioprotective protection with
RAAS intervention strategies.
ALBUMINURIA AS A MARKER OF
END-ORGAN DAMAGE
Renal
There is ample evidence that albumin is a good risk
marker for renal disease progression. This is seen, in par-
ticular, in overt proteinuric patients with nephropathy, as
well as in microalbuminuric patients with diabetes. Only
recently, Iseki et al had long enough follow-up to relate
albuminuria, albeit dipstick measured, to renal outcome
in the general population; the higher the albuminuria, the
more end-stage renal disease was observed [7]. Recently,
Verhave et al showed in the PREVEND study that al-
ready slight increases in the level of accurately measured
urinary albumin are associated with an increased chance
to lose kidney function [8].
Cardiovascular
The evidence for CV risk being associated with albumin
leakage in the urine is ample. In the general population,
overt albuminuria had been associated with markedly
increased CV morbidity and mortality in the Framing-
ham study conducted years ago [9]. More recently, ac-
curate measurements of urine albumin excretion were
available, which allowed identification of a CV risk being
associated with only slightly increased levels of albumin
excretion in the general population in the Danish Mon-
itoring Trends and Determinants in Cardiovascular Dis-
ease (MONICA) study [10], the PREVEND study [11],
and the Nord-Trondelag Health (HUNT) study [12]. Hil-
lege et al also clearly indicated that the relation between
albuminuria and CV risk is continuous, even at normal
albumin levels (Fig. 2). Also, the hypertensive popula-
tion shows a similar relation in the MONICA study [13],
the HOPE study [14], and the Losartan Intervention For
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Fig. 1. The effect of ACE-inhibition treatment to protect the heart after myocardial infarction is effective, particularly in those with reduced renal
function. Data from [3].
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Fig. 2. Blood pressure and albuminuria as
predictors of morbidity and mortality. Left
panel shows the total mortality data from the
Life Insurance data (1.3 million subjects 1925–
1939) with increasing systolic blood pressure.
Right panel shows the data from the PRE-
VEND study showing CV mortality in rela-
tion to baseline albuminuria levels [11].
End Point Reduction in Hypertension (LIFE) study [15].
In diabetes, there is, again, ample evidence of albumin-
uria as a CV risk predictor following the initial report by
Mogensen in 1984 [16].
Thus, there is no doubt that the level of albumin in
the urine is an excellent marker both for CV as well as
renal risk of patients with existing disease, and even in
the general healthy population.
CV AND RENAL PROTECTION BY REDUCING
ALBUMINURIA
The most important question that remains is what
would happen if we reduce urinary albumin excretion?
Would that afford equivalent cardiac and renal protec-
tion?
Before answering this question, it is at least intrigu-
ing to observe that recent cardiac and renal protec-
tive therapies that added to blood pressure lowering,
per se, are the introduction of tools to intervene in the
RAAS, such as ACE inhibitors and angiotensin II an-
tagonists. These drugs add to CV and renal protection
beyond blood pressure control as evidenced, for exam-
ple, in the IRMA2 [17], REIN [18], IDNT [19], and RE-
NAAL [20] trials for renal endpoints and, for example,
in the HOPE [21] and LIFE studies [22] for CV end
points.
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The fact that these RAAS interventions render such
an additive effect has obviously at first been attributed to
a reduction of circulating or organ angiotensin II levels
or other RAAS parameters. However, both ACEI and
angiotensin II antagonists, as well as renin inhibitors, all
share a clear antialbuminuric effect beyond their anti-
hypertensive effects. Because albuminuria has been as-
sociated with CV and renal risk, one wonders how far
the effects on proteinuria explain the organ protection
of RAAS inhibition. Even if this relation is not directly
causal, one may use albuminuria and its reduction as a
marker for effectiveness of therapy.
Indeed, albuminuria reduction has been clearly iden-
tified as being predictive for long-term renal outcome
in many studies. Recently, de Zeeuw et al analyzed this
in the RENAAL trial and showed that initial antialbu-
minuric effect of treatment is markedly associated with
renal protection [23]. In fact, the additive protective ef-
fect of the angiotensin II antagonist losartan could be
nearly fully explained by its antiproteinuric effect. Sim-
ilar data were obtained for CV protection: the more
medication initially reduced urine albumin excretion, the
better the CV system was protected in the long run [24].
Similar renal data were found in Atkins et al in the IDNT
trial [25]. Data on less-compromised subjects and patients
are still limited. In hypertensive diabetics with microal-
buminuria, Parving et al showed that the more you lower
albuminuria initially, the better you are protected in the
long run against diabetic nephropathy [17]. In the LIFE
trial, the data appear to be similar when treating pa-
tients with hypertension with left ventricular hypertro-
phy without selection for albuminuria [26]. Very recent
data have been presented by Asselbergs et al out of the
PREVEND Intervention Trial, showing that reducing al-
buminuria with ACE inhibition offers CV protection in
healthy volunteers, with only microalbuminuria as entry
criterium in the trial [27].
Thus, there are multiple data that link the degree of
therapy-induced albuminuria reduction to CV and re-
nal protection. Whether this is solely linked to RAAS
intervention or to other albuminuria-reducing therapies
remains to be proven in a prospective study.
CONCLUSION
There is ample evidence that risk stratification for end-
organ damage should include excreted proteins in the
urine (albuminuria) as well as eGFR, next to age, gen-
der, blood pressure levels, cholesterol levels, body weight,
smoking, diabetes, and so forth. Given the high resid-
ual CV and renal risk under conventional risk-reduction
strategies, the enormous impact of albuminuria on patient
morbidity and mortality, and the marked predictive value
of albuminuria lowering on CV and renal protection, one
should use the current drug armamentarium to specifi-
cally target albuminuria and reduce it as effectively as
possible separate from other risk factors. Because resid-
ual albuminuria under effective therapy is as detrimental
as without therapy, future efforts should be committed
toward more effective proteinuria lowering.
The fact that reduced renal function, be it increased
urinary albumin excretion or decreased filtration power,
enhances the vulnerability of the CV system for progres-
sive failure, and that renoprotective strategies are directly
related to CV protection, suggest that the way to a better
heart is through a better kidney. This opens the door for
multiorgan disease management and therapy in a disease
with multiorgan failure, like type 2 diabetes.
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